IN ELDERLY patients with atrial fibrillation or venous thromboembolism, novel oral anticoagulants are just as effective as warfarin but have distinct bleeding patterns, a systematic review has found. British researchers analysed data from 30,000 patients aged 75 or older in 19 randomised controlled trials. Major bleeding was significantly less likely with apixaban and there was a non-significant increased risk with dabigatran, when compared with vitamin K antagonists (VKA). Dabigatran caused more gastrointestinal bleeding but less intracranial bleeding than VKA. Apixaban also had a lower risk of intracranial bleeding compared with VKA. Circulation 2015; online 20 ...
The following articles have the tag atrial fibrillation
SHOULD all older patients be screened for atrial fibrillation (AF)?
LONG-TERM sustained weight loss can lead to freedom from atrial fibrillation (AF) in obese patients without the use of drugs or surgical intervention, Australian research shows.
MORE than 51,000 Australians will have a stroke this year and South Australia and Tasmania carry the highest burden of stroke in the country, a report shows.
OPPORTUNISTIC screening for asymptomatic atrial fibrillation (AF) could be a cost-effective way to reduce the risk of stroke and premature death, research suggests.
THE manufacturer of the oral anticoagulant dabigatran (Pradaxa) will pay $700 million to thousands of US patients who filed lawsuits against the company alleging they experienced bleeding while on the drug.
DESPITE increasingly positive safety and efficacy data for new oral anticoagulants (NOACs) and reports of an antidote becoming available in two years, warfarin still has a place in therapy, according to an international expert.
THE new oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) lowers the risk of intracranial haemorrhage and death compared to warfarin but increases the risk of major gastrointestinal bleeding, according to a major FDA review.
PHARMACY-based screening for undiagnosed atrial fibrillation (AF) using an iPhone app could help identify thousands of Australians at risk of stroke.
GPs say they have not been sufficiently educated about using new oral anticoagulants (NOACs) and 70% say the lack of an antidote is a concern, an MO poll has shown.
A SEPTEMBER PBS listing is expected for dabigatran (Pradaxa), more than two years after it was first recommended for reimbursement.
NEW generation antithrombotic dabigatran is expected be listed on the PBS for stroke prevention in September, more than two years after it was first approved for government reimbursement.
DOCTORS should exercise caution when changing patients to dabigatran (Pradaxa, Boehringer Ingelheim), an expert has warned, after research found the risks of thrombosis and bleeding were increased in previous warfarin users.
THE increasing prevalence of atrial fibrillation (AF), together with some confusion about the optimal use of catheter ablation, has prompted the development of Australia’s first consensus statement to guide treatment of AF.
CONFUSION about the optimal use of catheter ablation and the increasing prevalence of atrial fibrillation (AF) has prompted the development of Australia’s first consensus statement to guide treatment.
PATIENTS with subclinical hyperthyroidism carry an increased risk of developing atrial fibrillation (AF) compared to those with normal thyroid function, a general practice-based study confirms.
AN FDA safety advisory and new clinical trial results are reassuring and add further weight to calls for Pradaxa (dabigatran) to be PBS listed for atrial fibrillation, experts say.
DESPITE improved treatment of atrial fibrillation (AF), there is little evidence any impact has been made on stroke burden, a study suggests.
SUBCLINICAL hyperthyroidism (SCH) is associated with a raised risk of incident atrial fibrillation (AF) and with death from coronary heart disease (CHD), a study suggests.
EVEN without a stroke, atrial fibrillation (AF) raises the risk of cognitive and functional decline, according to an analysis of two randomised controlled trials of treatments to reduce cardiovascular disease.
AT LEAST 50,000 Australians aged 40 years or more may have atrial fibrillation (AF) without knowing it, new data suggest.
A DRUG company push to enlist doctors and patients into pressuring the federal government to subsidise the warfarin alternative dabigatran has been branded “appalling” and “inappropriate”.
MODELLING suggests the anticoagulant dabigatran offers a positive benefit compared to warfarin in the management of non-valvular atrial fibrillation (AF), researchers say.
MORTALITY rates from stroke in patients with atrial fibrillation (AF) are excessively high and a contributing factor may be the under-prescribing of anticoagulants, Australian experts say. Researchers from the University of New South Wales (UNSW) and the Ingham Institute looked at nearly 27,000 cases of ischaemic stroke occurring between 2000 and 2006 in the Program of Research Informing Stroke Management (PRISM) study, and found that a quarter were due to atrial fibrillation (AF). Patients with AF were twice as likely to die in hospital and had mortality rates of nearly 40% ...
EXPERTS in ethics and quality use of medicines have voiced concern over the continued use of patient familiarisation programs, suggesting they are more about pitching to consumers than good clinical practice. The comments follow last week's announcement by Boehringer Ingelheim that doctors will be able to enrol their atrial fibrillation patients in a program that will see them receive free dabigatran (Pradaxa). The national product familiarisation program (PFP) will allow doctors to enrol up to 10 patients to receive the drug - ahead of any PBS listing. Professor Paul Komesaroff, chair of the ethics committee at ...
THE oral thrombin inhibitor dabigatran has been approved for listing on the PBS for use in patients with atrial fibrillation (AF) under a new pilot, fast-track regulatory process. Dabigatran (Pradaxa) reimbursement was approved at the March meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) for use in patients with AF at risk of stroke on the basis of “acceptable cost-effectiveness”. However, TGA approval was granted only today, a Health Department spokesperson confirmed. Dabigatran was one of a number of drugs approved as part of a pilot run by the department, allowing for expedited reimbursement review, a spokesman ...
Patients with any first-degree relative with atrial fibrillation (AF) have a significantly increased risk of developing the condition themselves, independently of traditional AF risk factors, experts say. Results from a US community-based prospective study of 4421 people free of AF at baseline show that those with a first-degree relative with AF had a 40% greater risk of developing AF themselves during an eight year follow-up. This increased risk was not attenuated after adjusting for age, sex, BMI, blood pressure, treatment for hypertension, heart murmur and heart failure, or having any of the four common AF-related genetic variants. ...
A decade ago, atrial fibrillation was considered an emerging epidemic – has it now reached its peak? Kate Woods looks at the rise and rise of AF.
A NEW report has highlighted the need for public awareness campaigns to improve knowledge of atrial fibrillation (AF), which experts say is under-diagnosed and often inadequately managed. The Economic Costs of Atrial Fibrillation in Australia report, prepared on behalf of the National Stroke Foundation, revealed AF costs the Australian health system more than $1.2 billion annually based on related hospitalisations, strokes, cardiovascular events and loss of productivity. According to the report, patients with AF had a seven times greater risk of stroke compared to the general population, and a three- times greater risk of heart failure. ...
MAJOR gaps exist in the knowledge of the cardiovascular risks associated with atrial fibrillation (AF), according to a recent international study which found that both patients and cardiologists may underestimate the seriousness of the condition. A survey of more than 1600 cardiologists and patients with AF in 11 countries, including Australia, revealed only 43% of cardiologists and 55% of patients considered AF to be life-threatening, despite the condition doubling the risk of death, and having a five times greater risk of stroke. Cardiologists also underestimated their patient’s understanding of the benefits of AF treatments and overestimated ...